Objectives: There has been little evidence so far supporting further surgical intervention in case of repeated recurrence of glioblastoma multiforme (GBM). Thus, the efficacy and utility of repeated resection remains unclear but worthy of consideration. The aim of this study was to review the efficacy of multiple repeated resections in patients with recurrent GBM.
G lioblastoma multiforme (GBM) is an aggressive malignant tumor characterized by recurrence within or adjacent to the original tumor site. The treatment goal for GBM is to achieve tumor control, prolong survival, and maintain quality of life. Contemporary standard treatment strategies include microsurgical resection of as much tumor as possible with preservation of neurological function, followed by adjuvant combined radiation-chemotherapy.
Gross-total resection is one of the most important predictors to improve overall survival of patients. [1] [2] [3] [4] Nevertheless, residual tumor causes relapse in almost all instances. GBM most frequently recurs after a median survival time of 32 to 36 weeks. 5, 6 Despite recent advances in surgical techniques and adjunctive therapies, the prognosis of patients with GBM remains dismal with a median survival of approximately 14.6 months, as shown by the long-term follow-up of the randomized phase III clinical trial carried out by the European Organisation for Research and Treatment of Cancer and the National Cancer Institute of Canada Clinical Trials Group. 7 In case of recurrent tumor, no standard therapy exists. Thus, treatment modalities and survival rates vary among neurooncological centres. Some patients may receive experimental targeted drugs. Despite that, reported survival rates have not relevantly improved. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In several studies, secondary resection has been suggested to improve the neurological function and overall survival rate. [19] [20] [21] However, there is only very little evidence so far supporting further resection in case of repeated tumor recurrence. 6, [22] [23] [24] [25] [26] [27] [28] [29] In general, no further surgical treatment is recommended after resection of the first recurrence. Therefore, the impact of repeated resections in recurrent GBM is not clear. Although repeated resection might be considered controversial, it is worthy of consideration, since thus far it has not been clarified whether repeated resection provides a survival benefit.
The aim of this study was to review retrospectively the effectiveness of multiple repeated resections in patients with recurrent GBM with regard to survival time. In addition, we evaluated the role of various risk factors, such as age, sex, histopathologic findings, location, extent of resection, Karnofsky Performance Status (KPS), and progression-free interval after repeated surgery.
MATERIALS AND METHODS

Patients
Forty-two patients who underwent repeated microsurgical resection for recurrent GBM between January 2006 and July 2010 were enclosed in this retrospective study. Patients who underwent multiple repeated microsurgical resections for recurrent GBM (group A) were compared with another group of patients who were treated nonsurgically after resection of the first recurrence GBM (group B).
Surgical and Postoperative Treatments
Microsurgical resection was performed according to standard surgical techniques for tumors not involving eloquent areas of the brain. Depending on tumor localization and the surgeons' preference, neuronavigation, electrophysiological mapping, and/or 5-aminolevulenic acid were applied intraoperatively. Gross-total microsurgical resection was achieved when the neurosurgeon determined that all areas of visible tumor were resected intraoperatively. A subtotal resection was defined when remnants of tumor were left behind. All patients underwent postoperative computed tomography scan within 6 hours.
After initial microsurgical resection, temozolomide (TMZ) was administered in 29 patients concurrently with radiotherapy according to current standard therapy. 7 Six patients received TMZ alone within the Neuroonkologische Arbeitsgemeinschaft (NOA) 8 protocol 30 and 2 patients received ACNU/VM26 within the NOA-1 protocol. 31 PCV chemotherapy was administered in 1 patient. 32 Thirty-eight patients received conventional-fractionated partial brain radiotherapy with a total dose of 54 to 60 Gy (single dose, 1.8 to 2.0 Gy) starting within 6 weeks after initial resection. Radiotherapy was delivered after computed tomography-based 3D-treatment planning using a thermoplastic mask fixation for immobilization. The target volume was defined on the basis of preoperative and, as far as available, postoperative MR images including contrast-enhancing tumor tissue, perifocal edema, and an adequate safety margin.
Clinical follow-up examinations including contrastenhanced MRI were performed usually at 3-month intervals after every microsurgical resection. MRI was also obtained if tumor progression was suspected clinically. KPS were obtained regularly at follow-up examinations.
Treatment modalities for tumor recurrence were decided collectively in a multidisciplinary tumor board including neurosurgeons, neurooncologists, radiation-oncologists, neuroradiologists, and neuropathologists.
Follow-up data, times to progression, and survival data were obtained by review of hospital files and supplemented by phone calls to the patients or to the primary physicians. Diagnosis of progression was made using contrast-enhanced MRI and/or progression of symptoms. 33 
Statistical Methods
The main outcome measures were overall survival, 2-year survival rate, and 3-year survival rate. JMP software (version 8.0, SAS Institute Inc., Cary, NC) was used for statistical analysis.
The survival rate and the 6-month progression-free survival 34 were estimated by the Kaplan-Meier method. Comparisons between the 2 groups were made by use of log-rank tests.
Potential prognostic factors included age, sex, tumor location, extent of resection at first recurrence, histologic findings, progression-free interval, and median KPS after the resection of first recurrence, which were examined by univariate and multivariate analyses. The Kaplan-Meier method and log-rank tests were used for the univariate analysis and to generate the time-toevent curves; the Cox proportional hazards regression model was used for multivariate analysis. Multivariate analysis was generated if the potential prognostic factors were significant on univariate analysis. To analyze the differences between groups, w 2 test was used. Summary data were presented as median. Statistical significance was defined as a probability value < 0.05.
RESULTS
Patient's Characteristics
Group A consisted of 10 patients (3 men and 7 women), whereas group B included 32 patients (16 men and 16 women). The median age of patients of group A was 60.5 years (range, 31 to 72 y) that was similar to that of patients of group B, which was 56.5 years (range, 32 to 74 y; P = 0.756). Six patients (60%) of group A and 16 patients (65.6%) of group B were younger than 65 years.
Initial microsurgical gross-total resection was achieved in 8 patients of group A (80%) and in 26 patients of group B (81.3%). At the first recurrence, gross-total resection was possible in 8 patients of group A (80%) and in 20 patients of group B (62.5%). In 2 patients (20%) of group A and in 12 patients (37.5%) of group B, GBM infiltrated eloquent areas, making a gross-total resection unfeasible. No significant difference in the extent of initial resection and resection of the first recurrence was found between groups (P = 0.930 and 0.290, respectively).
Overall, 6 patients of group A underwent microsurgical resection 3 times, 3 patients 4 times, and 1 patient 6 times ( Fig. 1 ).
Histopathologic findings revealed typical GBM in 8 patients (80%) of group A and in 23 patients (78.1%) of group B. An oligodendroglial component was detected in 2 patients (20%) of group A and in 7 patients (21.9%) of group B. There was no difference between groups (P = 0.899).
The median KPS after resection of the first recurrence was 80 in both groups. All patients (100%) of group A and 18 patients (56.2%) of group B had a KPS of at least 80. No statistically significant difference of median KPS between both groups was found (P = 0.084).
After resection of the first recurrence, 6 patients (60%) of group A had a progression-free interval for > 3 months. In contrast, only 10 patients (31.2%) of group B were free of tumor recurrence within 3 months postoperatively. This difference was not significant (P = 0.072).
The 6-month progression-free survival rates were 70.0% (group A) and 87.5% (group B) after the initial resection and 40.0% and 19.4%, respectively, after resection of the first recurrence. The differences again failed to reach statistical significance (P = 0.176 and 0.144, respectively; Figs. 2A, B) .
Clinical characteristics of the patients are summarized in Table 1 .
Postoperative Complications
Surgical intervention for complications was necessary in 10 patients (3 of group A and 7 of group B) with postoperative complications. The most common of them was poor wound healing (n = 6), which occurred in 3 patients in each group. Furthermore, subdural hematoma (n = 2), cerebral abscess (n = 1), and hydrocephalus (n = 1) were found in 5 patients of group 2.
Salvage Postsurgical Treatment
After resection of the first recurrence, salvage treatment consisting of chemotherapy with ACNU (n = 1), CCNU (n = 1), and TMZ (n = 2) was performed in 4 patients of group A. Fourteenn patients of group B received similar treatment consisting of chemotherapy with ACNU (n = 2), PCV (n = 2), TMZ (n = 9), and cediranib (n = 1). Furthermore, 2 patients of group B received fractionated partial brain radiotherapy after resection of the first recurrence. Combined treatment with radiochemotherapy was performed in 2 patients of group A with CCNU (n = 1) and TMZ (n = 1), as well as in 3 patients of group B with ACNU and bevacizumab (n = 1) and ACNU alone (n = 2), followed with fractionated partial brain radiotherapy with a total dose of 30 to 56 Gy (single dose, 1.8 to 4.0 Gy).
Impact of Repeated Resections on Survival
The follow-up time of all patients ranged from 5 to 86 months with a median of 35.5 months. Thirty-two patients died due to disease progression. The median overall survival for the entire population was 19 months (range, 4 to 41 mo; Fig. 3A ). The median overall survival time of group A was markedly higher than that of group B (26 vs. 16 mo; P = 0.052; Fig. 3B ).
Furthermore, 2-year survival rate was 58.3% in patients of group A and 29.0% in patients of group B ( Table 2 ; P = 0.036). Likewise, it turned out that 3-year survival rate of patients of group A (31.1%) was also significantly higher compared with that of patients of group B (12.4%; P = 0.038).
Univariate analysis demonstrated patient's age and progression-free interval as factors that have an influence on survival. Multivariate analysis revealed only progressionfree interval as significant independent prognostic factor (P = 0.01; Table 3 ). 
DISCUSSION
Recurrent GBM is frequently associated with more aggressive tumor biology and with resistance to adjuvant therapy. [35] [36] [37] Data on the effect of reirradiation, applied as normofractionated or hypofractionated stereotactic small volume radiotherapy are limited regarding further tumor growth, but it may aggravate neurological toxicity. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] In long-term survivors, there are concerns regarding radiation-induced late sequelae, in particular delayed leukoencephalopathy with neurocognitive dysfunction or radiation necrosis. [48] [49] [50] It was shown that chemotherapy after surgery for the initial tumor is significantly correlated with time to tumor progression and survival, but the role of chemotherapy in recurrence has not been fully elucidated, and chemotherapy can be problematic with regard to the biological status of the tumor and the increased risk of cumulative toxicity. Therefore, in most cases, patients with recurrent GBM do not have comprehensive treatment options as those with newly diagnosed GBM. Therefore, repeated resections could be a valuable option to improve survival.
Our study shows a markedly higher survival time in patients who underwent multiple repeated microsurgical resections as compared with that of those who were treated nonsurgically after resection of the first recurrence with an absolute observed improvement of about 10 months.
Moreover, there was a significantly higher 2-year and 3-year survival rate in favour of patients who underwent multiple repeated microsurgical resections. This finding is important, because repeated resections may give patients more chance to achieve a long-term survival. Of course, we cannot exclude selection bias. Nevertheless, our study clearly shows that repeated surgery has distinct advantages.
A positive correlation between survival and extent of resection has been described previously. [51] [52] [53] [54] In one of the largest series of glioblastoma long-term survivors with a survival time of > 36 months, 22% of patients had a third operation and 7% patients had a fourth operation in addition to radio/chemotherapy. 27 Repeated resection may result in improvement of neurological deficits and lead to lower seizure incidence or even abolishing them, which is most likely caused by reduction of intracranial pressure. 33 Because rapid clinical decline caused by increased intracranial pressure is most often a negative prognostic factor, repeated resection might be expected to improve quality of life, which, however, has yet to be proven. Because this study was performed retrospectively, it was not possible to evaluate the quality of life of patients through a validate questionnaire.
The role of radio/chemotherapy has been reported to be of added value in recurrent GBM after repeated resection. 28 On the other side, repeated resection may also increase the likelihood of response to radio/chemotherapy, particularly with regard to cytoreduction, and ultimately improve survival, as shown after aggressive resection of GBM. 55 Furthermore, a radiologic progressive lesion after postoperative radio/chemotherapy (ie, tumor progression or radionecrosis, or both) can be histologically verified by reresection. 56 Several studies have demonstrated age as a strong independent variable of survival. 57, 58 The survival of patients with GBM is also correlated with KPS. Patients with a KPS < 80 have a higher relative risk of poor survival compared with those with a KPS score of 80 or above. 57 We found, however, that age lost its significance when it entered the final step in the multivariate analysis, and KPS was not significant in univariate analysis. Detection of oligodendroglial component suggests less aggressive tumor and has been reported to be associated with improved prognosis. 59 In the present study, however, no such correlation was found with survival in the univariate analysis. As indicated, progression-free interval after resection of the first recurrence remained the major significant independent variable in the multivariate analysis. On the basis of our results, we found that principally there is no limit of the number of resections given that the tumor still appears as a circumscribed lesion. Nevertheless, repeated resections should be performed only after careful consideration of risk and benefit, with special regard to quality of life and patient's wish for prolonged survival. Preoperative planning needs to be carefully assessed. Adjunctive surgical technologies including neuronavigation, 60 functional MRI, 61 cortical mapping, 62 5-aminolevulenic acid, 1 or combined techniques 63,64 may help to achieve more extensive resection with preservation of eloquent areas and to improve overall outcome.
Although our results demonstrate possible benefits of repeated surgical resections of GBM recurrence, we acknowledge several limitations of the present study. Repeated surgical resections were performed in patients, who were supposed to have benefit in survival time, or on wish of patient or of the caretaker. It would be also useful to confirm and extend our results in a larger study population, because our study is limited by the relatively small sample size. Survival may also be biased by diverse adjuvant treatment. Furthermore, this observation was conducted retrospectively, and it was unfortunately not possible for us to determine molecular cytogenetic profiles retrospectively (ie, methylation of MGMT promoter gene, 1p/19q co-deletion, IDH1 mutation), which might also play an important role in survival rate of patients with recurrent GBM. Nevertheless, despite these limitations, our study underlines the benefit of repeated surgical resections with longer survival in patients with GBM recurrence, particularly when a long progression-free interval has been present.
CONCLUSIONS
In conclusion, our results are in support of a role for repeated surgical resections of GBM recurrences in a selected group of patients with respect to long-term survival and demonstrate a higher risk for manageable postoperative complications. Repeated surgical resection may be considered as a first line treatment option in addition to radio/chemotherapy in GBM recurrence. The decision to repeat the surgical resection can only be made individually, ideally after assessment in an interdisciplinary tumor board. Larger randomized controlled studies with molecular cytogenetic analysis are needed to validate survival benefit with repeated microsurgical resections within a multimodal strategy. 
